Abstract
Mast cell activation releases the mediators associated with type I allergy. As such, the study of mast cell activation is critical for understanding the allergic reaction, and for developing methods to control it. Importantly, another ligand receptor pair (compound 48/80 and MRGPRX2) that activates mast cells in addition to allergen-IgE-FcεRI has been identified. As mast cells mature in tissue from hematopoietic stem cells, their physiology and pathophysiology is difficult to study. Mast cell lines and mast cells cultured from stem cells are often studied instead of tissue mast cells. There has been some progress in the description of the mechanism of the activation of mast cells, substances limiting mast cell activation and in the catalogue of proteases that mast cells express. Basophil granulocytes express FcεRI, bind IgE and respond to allergen crosslinking in a very similar fashion to mast cells. In the recent literature, basophils were mistakenly described as antigen-presenting cells; this has convincingly been disputed in a number of subsequent publications. Their function in physiology and pathophysiology is not known, but they are frequently used to document allergic sensitisation in the basophil activation test. Significant progress has been made in documenting the relevance of basophil activation as a second-line test in allergy diagnosis. Basophil reactivity and sensitivity may reflect symptom severity and allergen threshold, and are used to document and monitor allergy. The physiology and pathophysiology of allergic effector cells remain an important area of research.
References
1.
Cavalcante MC, Allodi S, Valente AP, Straus AH, Takahashi HK, Mourão PA, et al: Occurrence of heparin in the invertebrate Styela plicata (Tunicata) is restricted to cell layers facing the outside environment: an ancient role in defense? J Biol Chem 2000;275:36189-36186.
2.
Motakis E, Guhl S, Ishizu Y, Itoh M, Kawaji H, de Hoon M, et al: Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. Blood 2014;123:e58-e67.
3.
McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al: Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237-241.
4.
Jensen BM, Frandsen PM, Raaby EM, Schiøtz PO, Skov PS, Poulsen LK: Molecular and stimulus-response profiles illustrate heterogeneity between peripheral and cord blood-derived human mast cells. J Leukoc Biol 2014;95:893-901.
5.
Andersen HB, Holm M, Hetland TE, Dahl C, Junker S, Schiøtz PO, et al: Comparison of short term in vitro cultured human mast cells from different progenitors - peripheral blood-derived progenitors generate highly mature and functional mast cells. J Immunol Methods 2008;336:166-174.
6.
Beasley RC, Featherstone RL, Church MK, Rafferty P, Varley JG, Harris A, et al: Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol 1989;66:1685-1693.
7.
Dichlberger A, Schlager S, Maaninka K, Schneider WJ, Kovanen PT: Adipose triglyceride lipase regulates eicosanoid production in activated human mast cells. J Lipid Res 2014;55:2471-2478.
8.
van den Elsen LWJ, Nusse Y, Balvers M, Redegeld FA, Knol EF, Garssen J, et al: n-3 long-chain PUFA reduce allergy-related mediator release by human mast cells in vitro via inhibition of reactive oxygen species. Br J Nutr 2013;109:1821-1831.
9.
Kirshenbaum AS, Petrik A, Walsh R, Kirby TL, Vepa S, Wangsa D, et al: A ten-year retrospective analysis of the distribution, use and phenotypic characteristics of the LAD2 human mast cell line. Int Arch Allergy Immunol 2014;164:265-270.
10.
Wang J-X, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A, et al: IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci USA 2014;111:10281-10286.
11.
Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff SC, et al: IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 2014;69:216-222.
12.
Lai Y, Altemeier WA, Vandree J, Piliponsky AM, Johnson B, Appel CL, et al: Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol 2014;133:1448-1455.
13.
Lefrançais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C, et al: Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci USA 2014;111:15502-15507.
14.
Enoksson M, Möller-Westerberg C, Wicher G, Fallon PG, Forsberg-Nilsson K, Lunderius-Andersson C, et al: Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood 2013;121:530-536.
15.
Jung M-Y, Smrz D, Desai A, Bandara G, Ito T, Iwaki S, et al: IL-33 Induces a hyporesponsive phenotype in human and mouse mast cells. J Immunol 2013;190:531-538.
16.
Lappalainen J, Rintahaka J, Kovanen PT, Matikainen S, Eklund KK: Intracellular RNA recognition pathway activates strong anti-viral response in human mast cells. Clin Exp Immunol 2013;172:121-128.
17.
Tsutsui-Takeuchi M, Ushio H, Fukuda M, Yamada T, Niyonsaba F, Okumura K, et al: Roles of retinoic acid-inducible gene-I-like receptors (RLRs), Toll-like receptor (TLR) 3 and 2'-5′ oligoadenylate synthetase as viral recognition receptors on human mast cells in response to viral infection. Immunol Res 2015;61:240-249.
18.
Marcet CW, St Laurent CD, Moon TC, Singh N, Befus AD: Limited replication of influenza A virus in human mast cells. Immunol Res 2013;56:32-43.
19.
Al-Afif A, Alyazidi R, Oldford SA, Huang YY, King CA, Haidl ID, et al: Respiratory syncytial virus infection of primary human mast cells induces the selective production of type I interferons, CXCL10, and CCL4. J Allergy Clin Immunol 2015;136:1346-1354.
20.
Yu Y, Yip KH, Tam IYS, Sam SW, Ng CW, Zhang W, et al: Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation. PLoS One 2014;9:e112989.
21.
Suurmond J, Dorjée AL, Knol EF, Huizinga TWJ, Toes REM: Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering. Clin Exp Allergy 2015;45:788-796.
22.
Keitel U, Schilling E, Knappe D, Al-Mekhlafi M, Petersen F, Hoffmann R, et al: Effect of antimicrobial peptides from Apis mellifera hemolymph and its optimized version Api88 on biological activities of human monocytes and mast cells. Innate Immun 2013;19:355-367.
23.
Pundir P, Catalli A, Leggiadro C, Douglas SE, Kulka M: Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. Mucosal Immunol 2014;7:177-187.
24.
Bąbolewska E, Brzezińska-Błaszczyk E: Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response. Cell Immunol 2015;293:67-73.
25.
Kawasaki H, Chang H-W, Tseng H-C, Hsu S-C, Yang S-J, Hung C-H, et al: A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy 2014;69:445-452.
26.
Nassiri M, Babina M, Dölle S, Edenharter G, Ruëff F, Worm M: Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015;135:491-499.
27.
Nakashima-Kaneda K, Matsuda A, Mizuguchi H, Sasaki-Sakamoto T, Saito H, Ra C, et al: Regulation of IgE-dependent zinc release from human mast cells. Int Arch Allergy Immunol 2013;161(suppl 2):44-51.
28.
MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, et al: The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol 2014;85:91-104.
29.
Rodewald H-R, Feyerabend TB: Widespread immunological functions of mast cells: fact or fiction? Immunity 2012;37:13-24.
30.
Inage E, Kasakura K, Yashiro T, Suzuki R, Baba Y, Nakano N, et al: Critical roles for PU.1, GATA1, and GATA2 in the expression of human FcεRI on mast cells: PU.1 and GATA1 transactivate FCER1A, and GATA2 transactivates FCER1A and MS4A2. J Immunol 2014;192:3936-3946.
31.
Yamada Y, Kosaka K, Miyazawa T, Kurata-Miura K, Yoshida T: miR-142-3p enhances FcεRI-mediated degranulation in mast cells. Biochem Biophys Res Commun 2014;443:980-986.
32.
Joulia R, Gaudenzio N, Rodrigues M, Lopez J, Blanchard N, Valitutti S, et al: Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence. Nat Commun 2015;6:6174.
33.
Krohn IK, Lund G, Frandsen PM, Schiøtz PO, Dahl R, Hoffmann HJ: Mast cell FcεRI density and function dissociate from dependence on soluble IgE concentration at very low and very high IgE concentrations. J Asthma 2013;50:117-121.
34.
Frandsen PM, Krohn IJMK, Hoffmann HJ, Schiøtz PO: The influence of IgE on cultured human mast cells. Allergy Asthma Immunol Res 2013;5:409-414.
35.
Mahajan A, Barua D, Cutler P, Lidke DS, Espinoza FA, Pehlke C, et al: Optimal aggregation of FcεRI with a structurally defined trivalent ligand overrides negative regulation driven by phosphatases. ACS Chem Biol 2014;9:1508-1519.
36.
Okayama Y, Matsuda A, Kashiwakura J-I, Sasaki-Sakamoto T, Nunomura S, Shimokawa T, et al: Highly expressed cytoplasmic FcεRIβ in human mast cells functions as a negative regulator of the FcRγ-mediated cell activation signal. Clin Exp Allergy 2014;44:238-249.
37.
Cruse G, Beaven MA, Ashmole I, Bradding P, Gilfillan AM, Metcalfe DD: A truncated splice-variant of the FcεRIβ receptor subunit is critical for microtubule formation and degranulation in mast cells. Immunity 2013;38:906-917.
38.
Erlich TH, Yagil Z, Kay G, Peretz A, Migalovich-Sheikhet H, Tshori S, et al: Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol 2014;134:460-469.
39.
Siegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung M, et al: Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol 2013;132:1388-1396.
40.
Craig SS, Schwartz LB: Tryptase and chymase, markers of distinct types of human mast cells. Immunol Res 1989;8:130-148.
41.
Irani AM, Schwartz LB: Human mast cell heterogeneity. Allergy Proc 1994;15:303-308.
42.
Kinoshita T, Sawai N, Hidaka E, Yamashita T, Koike K: Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34+ cord blood cells. Blood 1999;94:496-508.
43.
Maaninka K, Lappalainen J, Kovanen PT: Human mast cells arise from a common circulating progenitor. J Allergy Clin Immunol 2013;132:463-469.e3.
44.
Hagel AF, deRossi T, Zopf Y, Konturek P, Dauth W, Kressel J, et al: Mast cell tryptase levels in gut mucosa in patients with gastrointestinal symptoms caused by food allergy. Int Arch Allergy Immunol 2013;160:350-355.
45.
Rönnberg E, Calounova G, Sutton VR, Trapani JA, Rollman O, Hagforsen E, et al: Granzyme H is a novel protease expressed by human mast cells. Int Arch Allergy Immunol 2014;165:68-74.
46.
García-Faroldi G, Rönnberg E, Orro A, Calounova G, Guss B, Lundequist A, et al: ADAMTS: novel proteases expressed by activated mast cells. Biol Chem 2013;394:291-305.
47.
Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al: The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015;70:1393-1405.
48.
Rodríguez-Romero A, Hernández-Santoyo A, Fuentes-Silva D, Palomares LA, Muñoz-Cruz S, Yépez-Mulia L, et al: Structural analysis of the endogenous glycoallergen Hev b 2 (endo-β-1,3-glucanase) from Hevea brasiliensis and its recognition by human basophils. Acta Crystallogr D Biol Crystallogr 2014;70:329-341.
49.
Pignatti P, Frossi B, Pala G, Negri S, Oman H, Perfetti L, et al: Oxidative activity of ammonium persulfate salt on mast cells and basophils: implication in hairdressers' asthma. Int Arch Allergy Immunol 2013;160:409-419.
50.
Gyimesi E, Gönczi F, Szilasi M, Pál G, Baráth S, Sipka S: The effects of various doses of bacterial lipopolysaccharide on the expression of CD63 and the release of histamine by basophils of atopic and non-atopic patients. Inflamm Res 2013;62:213-218.
51.
Matsuo H, Yokooji T, Morita H, Ooi M, Urata K, Ishii K, et al: Aspirin augments IgE-mediated histamine release from human peripheral basophils via Syk kinase activation. Allergol Int 2013;62:503-511.
52.
Witting Christensen SK, Kortekaas Krohn I, Thuraiaiyah J, Skjold T, Schmid JM, Hoffmann HJH: Sequential allergen desensitization of basophils is non-specific and may involve p38 MAPK. Allergy 2014;69:1343-1349.
53.
Mills K, Lay J, Wu W, Robinette C, Kesic MJ, Dreskin SC, et al: Vitamin E, γ-tocopherol, diminishes ex vivo basophil response to dust mite allergen. Allergy 2014;69:541-544.
54.
Watson BM, Oliveria JP, Nusca GM, Smith SG, Beaudin S, Dua B, et al: Inhibition of allergen-induced basophil activation by ASM-024, a nicotinic receptor ligand. Int Arch Allergy Immunol 2014;165:255-264.
55.
Nilsson N, Nilsson C, Hedlin G, Johansson SGO, Borres MP, Nopp A: Combining analyses of basophil allergen threshold sensitivity, CD-sens, and IgE antibodies to hydrolyzed wheat, ω-5 gliadin and timothy grass enhances the prediction of wheat challenge outcome. Int Arch Allergy Immunol 2013;162:50-57.
56.
Ford LS, Bloom KA, Nowak-Węgrzyn AH, Shreffler WG, Masilamani M, Sampson HA: Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow's milk tolerance. J Allergy Clin Immunol 2013;131:180-186.e1-e3.
57.
Ebo DG, Swerts S, Sabato V, Hagendorens MM, Bridts CH, Jorens PG, et al: New food allergies in a European non-Mediterranean region: is Cannabis sativa to blame? Int Arch Allergy Immunol 2013;161:220-228.
58.
Myrset HR, Fæste CK, Kristiansen PE, Dooper MMBW: Mapping of the immunodominant regions of shrimp tropomyosin Pan b 1 by human IgE-binding and IgE receptor crosslinking studies. Int Arch Allergy Immunol 2013;162:25-38.
59.
Mayorga C, Gomez F, Aranda A, Koppelman SJ, Diaz-Perales A, Blanca-López N, et al: Basophil response to peanut allergens in Mediterranean peanut-allergic patients. Allergy 2014;69:964-968.
60.
Chen X, Wang Q, El-Mezayen R, Zhuang Y, Dreskin SC: Ara h 2 and Ara h 6 have similar allergenic activity and are substantially redundant. Int Arch Allergy Immunol 2013;160:251-258.
61.
Glaumann S, Nopp A, Johansson SGO, Borres MP, Nilsson C: Oral peanut challenge identifies an allergy but the peanut allergen threshold sensitivity is not reproducible. PLoS One 2013;8:e53465.
62.
Homšak M, Silar M, Berce V, Tomazin M, Skerbinjek-Kavalar M, Celesnik N, et al: The relevance of basophil allergen sensitivity testing to distinguish between severe and mild peanut-allergic children. Int Arch Allergy Immunol 2013;162:310-317.
63.
Santos AF, Douiri A, Bécares N, Wu S-Y, Stephens A, Radulovic S, et al: Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol 2014;134:645-652.
64.
Santos AF, Du Toit G, Douiri A, Radulovic S, Stephens A, Turcanu V, et al: Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut. J Allergy Clin Immunol 2015;135:179-186.
65.
Song Y, Wang J, Leung N, Wang LX, Lisann L, Sicherer SH, et al: Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges. Ann Allergy Asthma Immunol 2015;114:319-326.
66.
Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, et al: IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 2015;135:1249-1256.
67.
Shi X, Guo R, White BL, Yancey A, Sanders TH, Davis JP, et al: Allergenic properties of enzymatically hydrolyzed peanut flour extracts. Int Arch Allergy Immunol 2013;162:123-130.
68.
Mayorga C, Andreu I, Aranda A, Doña I, Montañez MI, Blanca-Lopez N, et al: Fluoroquinolone photodegradation influences specific basophil activation. Int Arch Allergy Immunol 2013;160:377-382.
69.
Leysen J, Uyttebroek A, Sabato V, Bridts CH, De Clerck LS, Ebo DG: Predictive value of allergy tests for neuromuscular blocking agents: tackling an unmet need. Clin Exp Allergy 2014;44:1069-1075.
70.
Korošec P, Šilar M, Eržen R, Čelesnik N, Bajrović N, Zidarn M, et al: Clinical routine utility of basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on individuals with negative venom-specific IgE antibodies. Int Arch Allergy Immunol 2013;161:363-368.
71.
Ebo DG, Faber M, Sabato V, Leysen J, Bridts CH, De Clerck LS: Component-resolved diagnosis of wasp (yellow jacket) venom allergy. Clin Exp Allergy 2013;43:255-261.
72.
Balzer L, Pennino D, Blank S, Seismann H, Darsow U, Schnedler M, et al: Basophil activation test using recombinant allergens: highly specific diagnostic method complementing routine tests in wasp venom allergy. PLoS One 2014;9:e108619.
73.
Irinyi B, Gyimesi E, Garaczi E, Bata ZS, Kemény L, Zeher M, et al: Extended diagnostic value of autologous serum skin test and basophil CD63 expression assay in chronic urticaria. Br J Dermatol 2013;168:656-658.
74.
Ye Y-M, Yang E-M, Yoo H-S, Shin Y-S, Kim S-H, Park H-S: Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci 2014;29:43-47.
75.
Chan Y-C, Ramadani F, Santos AF, Pillai P, Ohm-Laursen L, Harper CE, et al: ‘Auto-anti-IgE': naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation. J Allergy Clin Immunol 2014;134:1394-1401.e4.
76.
Hatada Y, Kashiwakura J, Hayama K, Fujisawa D, Sasaki-Sakamoto T, Terui T, et al: Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients. Int Arch Allergy Immunol 2013;161(suppl 2):154-158.
77.
Čelesnik N, Vesel T, Rijavec M, Šilar M, Eržen R, Košnik M, et al: Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response. Allergy 2012;67:1594-1600.
78.
Bidad K, Nawijn MC, van Oosterhout AJM, van der Heide S, Elberink JNGO: Basophil activation test in the diagnosis and monitoring of mastocytosis patients with wasp venom allergy. Cytometry B Clin Cytom 2014;86:183-190.
79.
Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ: Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. J Allergy Clin Immunol 2014;134:741-744.e5.
80.
Kepil Özdemir S, Sin BA, Güloğlu D, İkincioğulları A, Gençtürk Z, Mısırlıgil Z: Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response? Int Arch Allergy Immunol 2014;164:237-245.
81.
Aasbjerg K, Backer V, Lund G, Holm J, Nielsen NC, Holse M, et al: Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417-428.
82.
Garrido-Fernández S, García BE, Sanz ML, Echechipía S, Lizaso MT, Tabar AI: Are basophil activation and sulphidoleukotriene determination useful tests for monitoring patients with peach allergy receiving sublingual immunotherapy with a Pru p 3-enriched peach extract? J Investig Allergol Clin Immunol 2014;24:106-113.
83.
Gericke J, Ohanyan T, Church MK, Maurer M, Metz M: Omalizumab may not inhibit mast cell and basophil activation in vitro. J Eur Acad Dermatol Venereol 2015;29:1832-1836.
84.
Pereira Santos MC, Campos Melo A, Caetano A, Caiado J, Mendes A, Pereira Barbosa M, et al: Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab. Eur Ann Allergy Clin Immunol 2015;47:38-40.
85.
Macglashan DW, Saini SS: Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 2013;132:906-911.e4.
86.
Gernez Y, Tirouvanziam R, Yu G, Ghosn EEB, Reshamwala N, Nguyen T, et al: Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. Int Arch Allergy Immunol 2011;154:318-327.
87.
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, et al: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-935.
88.
Metz M, Ohanyan T, Church MK, Maurer M: Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014;73:57-62.
89.
Hill DA, Siracusa MC, Ruymann KR, Tait Wojno ED, Artis D, Spergel JM: Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children. Allergy 2014;69:674-677.
90.
Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P, et al: Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol 2014;133:1709-1719.e8.
91.
Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M: Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 2011;66:961-968.
92.
Buschor P, Eggel A, Zellweger F, Stadler BM, Vogel M: Improved FcγRIIb targeting functionally translates into enhanced inhibition of basophil activation. Int Arch Allergy Immunol 2014;163:206-214.
93.
Salter BM, Oliveria JP, Nusca G, Smith SG, Watson RM, Comeau M, et al: Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. J Allergy Clin Immunol 2015;136:1636-1644.
94.
Dijkstra D, Hennig C, Hansen G, Biller H, Krug N, Hohlfeld JM: Identification and quantification of basophils in the airways of asthmatics following segmental allergen challenge. Cytometry A 2014;85:580-587.
95.
Nopp A, Cardell LO, Johansson SGO: CD-sens can be a reliable and easy-to-use complement in the diagnosis of allergic rhinitis. Int Arch Allergy Immunol 2013;161:87-90.
96.
Gómez E, Campo P, Rondón C, Barrionuevo E, Blanca-López N, Torres MJ, et al: Role of the basophil activation test in the diagnosis of local allergic rhinitis. J Allergy Clin Immunol 2013;132:975-976.e5.
97.
Commins SP, James HR, Stevens W, Pochan SL, Land MH, King C, et al: Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2014;134:108-115.
98.
Koketsu R, Yamaguchi M, Suzukawa M, Tanaka Y, Tashimo H, Arai H, et al: Pretreatment with low levels of FcεRI-crosslinking stimulation enhances basophil mediator release. Int Arch Allergy Immunol 2013;161(suppl 2):23-31.
99.
Suurmond J, Stoop JN, Rivellese F, Bakker AM, Huizinga TWJ, Toes REM: Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells. Eur J Immunol 2014;44:386-396.
100.
Boita M, Heffler E, Pizzimenti S, Raie A, Saraci E, Omedè P, et al: Regulation of B-cell-activating factor expression on the basophil membrane of allergic patients. Int Arch Allergy Immunol 2015;166:208-212.
101.
Falkencrone S, Poulsen LK, Bindslev-Jensen C, Woetmann A, Odum N, Poulsen BC, et al: IgE-mediated basophil tumour necrosis factor alpha induces matrix metalloproteinase-9 from monocytes. Allergy 2013;68:614-620.
102.
Duriancik DM, Hoag KA: Mistaken identity: purified basophils likely contaminated with dendritic cells. Cytometry A 2014;85:570-572.
103.
Hammad H, Plantinga M, Deswarte K, Pouliot P, Willart MAM, Kool M, et al: Inflammatory dendritic cells - not basophils - are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J Exp Med 2010;207:2097-2111.
104.
Rydnert F, Lundberg K, Greiff L, Lindstedt M: Circulating CD1c+ DCs are superior at activating Th2 responses upon Phl p stimulation compared with basophils and pDCs. Immunol Cell Biol 2014;92:557-560.
105.
Sharma M, Kaveri SV, Bayry J: Human basophils lack the capacity to drive memory CD4+ T cells toward the IL-22 response. J Allergy Clin Immunol 2013;132:1457-1458.
106.
Voskamp AL, Prickett SR, Mackay F, Rolland JM, O'Hehir RE: MHC class II expression in human basophils: induction and lack of functional significance. PLoS One 2013;8:e81777.
107.
Gaudenzio N, Laurent C, Valitutti S, Espinosa E: Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype. J Allergy Clin Immunol 2013;131:1400-1407.e11.
108.
Sharma M, Stephen-Victor E, Poncet P, Kaveri SV, Bayry J: Basophils are inept at promoting human Th17 responses. Hum Immunol 2015;76:176-180.
109.
Säfholm J, Manson ML, Bood J, Delin I, Orre A-C, Bergman P, et al: Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J Allergy Clin Immunol 2015;136:1232-1239.e1.
110.
Yip K-H, Kolesnikoff N, Yu C, Hauschild N, Taing H, Biggs L, et al: Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol 2014;133:1356-1364.e14.
111.
Nagai K, Tahara-Hanaoka S, Morishima Y, Tokunaga T, Imoto Y, Noguchi E, et al: Expression and function of Allergin-1 on human primary mast cells. PLoS One 2013;8:e76160.
112.
Cheng C, Ng DSW, Chan TK, Guan SP, Ho WE, Koh AHM, et al: Anti-allergic action of anti-malarial drug artesunate in experimental mast cell-mediated anaphylactic models. Allergy 2013;68:195-203.
113.
Hagenlocher Y, Bergheim I, Zacheja S, Schäffer M, Bischoff SC, Lorentz A: Cinnamon extract inhibits degranulation and de novo synthesis of inflammatory mediators in mast cells. Allergy 2013;68:490-497.
114.
Hoffmann K, Xifró RA, Hartweg JL, Spitzlei P, Meis K, Molderings GJ, et al: Inhibitory effects of benzodiazepines on the adenosine A2B receptor mediated secretion of interleukin-8 in human mast cells. Eur J Pharmacol 2013;700:152-158.
115.
Ko Y-J, Kim H-H, Kim E-J, Katakura Y, Lee W-S, Kim G-S, et al: Piceatannol inhibits mast cell-mediated allergic inflammation. Int J Mol Med 2013;31:951-958.
116.
Lee YS, Hur S, Kim T-Y: Homoisoflavanone prevents mast cell activation and allergic responses by inhibition of Syk signaling pathway. Allergy 2014;69:453-462.
117.
Weng Z, Patel AB, Panagiotidou S, Theoharides TC: The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 2015;135:1044-1052.e5.
118.
Cho MS, Park WS, Jung W-K, Qian Z-J, Lee D-S, Choi J-S, et al: Caffeic acid phenethyl ester promotes anti-inflammatory effects by inhibiting MAPK and NF-κB signaling in activated HMC-1 human mast cells. Pharm Biol 2014;52:926-932.
119.
Balletta A, Lorenz D, Rummel A, Gerhard R, Bigalke H, Wegner F: Clostridium difficile toxin B inhibits the secretory response of human mast cell line-1 (HMC-1) cells stimulated with high free-Ca2+ and GTPγS. Toxicology 2015;328:48-56.
120.
Umemoto EY, Speck M, Shimoda LMN, Kahue K, Sung C, Stokes AJ, et al: Single-walled carbon nanotube exposure induces membrane rearrangement and suppression of receptor-mediated signalling pathways in model mast cells. Toxicol Lett 2014;229:198-209.
121.
Dellinger AL, Zhou Z, Kepley CL: A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses. Nanomedicine 2014;10:1185-1193.
122.
Leysen J, De Witte L, Sabato V, Faber M, Hagendorens M, Bridts C, et al: IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: lessons from flow cytometry. Cytometry B Clin Cytom 2013;84:65-70.
123.
Philipse E, Sabato V, Bridts C, De Clerck L, Ebo D: Basophil activation in the diagnosis of life-threatening hypersensitivity reaction to iodinated contrast media: a case report. Acta Clin Belg 2013;68:140-142.
124.
Iwamoto T, Hirai H, Yamaguchi N, Kobayashi N, Sugimoto H, Tabata T, et al: Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcεRI. Cancer Sci 2014;105:1472-1479.
125.
Marraccini P, Digiesi G, Pignatti P, Bordini L, Previdi M: A clinical case of occupational allergy to piperacilline - a novel diagnostic method: basophil activation test (BAT) (in Italian). Med Lav 2013;104:434-439.
126.
Hino M, Shimojo N, Ochiai H, Inoue Y, Ando K, Chikaraishi K, et al: Expression of CD203c on basophils as a marker of immunoglobulin E-mediated L-asparaginase allergy. Leuk Lymphoma 2014;55:92-96.
127.
Uyttebroek AP, Sabato V, Leysen J, Bridts CH, De Clerck LS, Ebo DG: Flowcytometric diagnosis of atracurium-induced anaphylaxis. Allergy 2014;69:1324-1332.
128.
Oltean BM, Ernst M, Renneker S, Bakheit MA, Seitzer U, Ahmed J: Whole antigenic lysates of Ixodes ricinus, but not Der-p2 allergen-like protein, are potent inducers of basophil activation in previously tick-exposed human hosts. Transbound Emerg Dis 2013;60(suppl 2):162-171.
129.
Michel S, Scherer K, Heijnen IAFM, Bircher AJ: Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat. Allergy 2014;69:403-405.
130.
Sugimoto N, Yamaguchi M, Tanaka Y, Nakase Y, Nagase H, Akiyama H, et al: The basophil activation test identified carminic acid as an allergen inducing anaphylaxis. J Allergy Clin Immunol Pract 2013;1:197-199.
131.
de las Marinas MD, Martorell C, Martorell A, Cerdá JC, Felix R, Guaita M, et al: Basophil activation test is a useful tool in occupational asthma due to iroko wood. J Investig Allergol Clin Immunol 2013;23:512-514.
132.
Della-Torre E, Pignatti P, Yacoub M-R, Sabbadini M-G, Colombo G: In vivo tests with ‘Tahini' sauce: new allergenic source to evaluate IgE-mediated hypersensitivity to sesame. Ann Allergy Asthma Immunol 2013;110:209-210.
133.
Viel S, Garnier L, Joly E, Rouzaire P, Nosbaum A, Pralong P, et al: The basophil activation test: a sensitive test in the diagnosis of allergic immediate hypersensitivity to pristinamycin. Int Arch Allergy Immunol 2015;167:94-98.
134.
Tanaka Y, Nakase Y, Yamaguchi M, Sugimoto N, Ohara K, Nagase H, et al: Allergy to formaldehyde: basophil histamine-release test is useful for diagnosis. Int Arch Allergy Immunol 2014;164:27-29.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
